Abu Bakar Hafeez Bhatti

Dr. Abu Bakar Hafeez Bhatti

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in The Journal of Emergency Medicine
Verified
Journal Article
Closed access
NMNabil Mahmood Mirza
Nabil Mahmood Mirza
AAAli Imran Amjad
Ali Imran Amjad
ABAbu Bakar Hafeez Bhatti
Abu Bakar Hafeez Bhatti
FMFatima Tuz Zahra Mirza
Fatima Tuz Zahra Mirza
KSKashif Shakoor Shaikh
Kashif Shakoor Shaikh
SISardar Zakariya Imam
Sardar Zakariya Imam

3 February 2016 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
ABAbu Bakar Hafeez Bhatti
Abu Bakar Hafeez Bhatti
FDFaisal Saud Dar
Faisal Saud Dar
AWAnum Waheed
Anum Waheed
KSKashif Shafique
Kashif Shafique
FSFaisal Sultan
Faisal Sultan
NSNajmul Hassan Shah
Najmul Hassan Shah
Hepatocellular carcinoma (HCC) ranks second amongst all causes of cancer deaths globally. It is on a rise in Pakistan and might represent the most common cancer in adult males. Pakistan contributes significantly to global burden of hepatitis C, which is a known risk factor for HCC, and has one of the highest prevalence rates (>3%) in the world. In the absence of a national cancer registry and screening programs, prevalence of hepatitis and HCC only represents estimates of the real magnitude of this problem. In this review, we present various aspects of HCC in Pakistan, comparing and contrasting it with the global trends in cancer care. There is a general lack of awareness regarding risk factors of HCC in Pakistani population and prevalence of hepatitis C has increased. In addition, less common risk factors are also on a rise. Majority of patients present with advanced HCC and are not eligible for definitive treatment. We have attempted to highlight issues that have a significant bearing on HCC outcome in Pakistan. A set of strategies have been put forth that can potentially help reduce incidence and improve HCC outcome on national level.

17 April 2015 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
FDFaisal Saud Dar
Faisal Saud Dar
ABAbu Bakar Hafeez Bhatti
Abu Bakar Hafeez Bhatti
ADAbdul‐Wahab Dogar
Abdul‐Wahab Dogar
HZHaseeb Zia
Haseeb Zia
SASadaf Amin
Sadaf Amin
NSNajmul Hassan Shah
Najmul Hassan Shah
Living donor liver transplantation (LDLT) is the only treatment option for patients with end‐stage liver disease (ESLD) where cadaveric donors are not available. In developing countries, the inception of LDLT programs remains a challenge. The first successful liver transplantation program in Pakistan started transplantation in 2012. The objective of this study was to report outcomes of 100 LDLT recipients in a developing country and to highlight the challenges encountered by a new LDLT program in a resource‐limited setting. We retrospectively reviewed recipients who underwent LDLT between April 2012 and August 2014. Demographics, etiology, graft characteristics, and operative variables were assessed. Outcome was assessed on the basis of morbidity and mortality. All complications of ≥ 3 on the Clavien‐Dindo grading system were included as morbidity. Estimated 1‐year survival was calculated using Kaplan‐Meier curves, and a Log‐rank test was used to determine the significance. Outcomes between the first 50 LDLTs (group 1) and latter 50 LDLTs (group 2) were also compared. Median age was 46.5 (0.5‐72) years, whereas the median MELD score was 15.5 (7‐37). The male to female ratio was 4:1. ESLD secondary to hepatitis C virus was the most common indication (73% patients). There were 52 (52%) significant (≥ grade 3) complications. The most common morbidities were bile leaks in 9 (9%) and biliary strictures in 14 (14%) patients. Overall mortality in patients who underwent LDLT for ESLD was 10.6%. Estimated 1‐year survival was 87%. Patients who underwent transplantation in the latter period had a significantly lower overall complication rate (36% versus 68%; P = 0.01). Comparable outcomes can be achieved in a new LDLT program in a developing country. Outcomes improve as experience increases. Liver Transpl 21:982‐990, 2015. © 2015 AASLD.

1 October 2014 in International Journal of Surgery
Verified
Journal Article
Closed access
ABAbu Bakar Hafeez Bhatti
Abu Bakar Hafeez Bhatti
AAAli Akbar
Ali Akbar
SKShahid Khattak
Shahid Khattak
AKAther Saeed Kazmi
Ather Saeed Kazmi
AJAarif Jamshed
Aarif Jamshed
ASAamir Ali Syed
Aamir Ali Syed
Rarely, patients with pathological complete response (PCR) after neoadjuvant chemoradiotherapy demonstrate acellular mucin pools. The prognostic significance of this finding is controversial. The objective of this study was to determine impact of acellular mucin pools on disease free and overall survival in patients with complete pathological response to neoadjuvant chemoradiotherapy in rectal cancer. One hundred and seventy two patients received neoadjuvant chemoradiotherapy for rectal cancer and underwent surgery. Patients were divided into two groups based on presence of acellular mucin pools. Locoregional failures, distant failures and deaths were compared. Expected 5 year disease free and overall survival was calculated. Median follow-up was 36(4-94) months. Complete pathological response was identified in 35(20.3%) patients. Of these, 12(34.2%) had acellular mucin pools in resected specimen. Majority of mucin negative tumors were moderately differentiated (78% vs 25%) (P = 0.005). Median overall survival for mucin positive and mucin negative tumors was 4(1.3-5.7) and 3.3(0.1-6.3) years respectively. Expected 5 year disease free and overall survival for mucin positive and mucin negative tumors was 73% and 89% (P = 0.1) and 75% and 87% (P = 0.4). Acellular mucin pools in rectal cancer following a PCR to neoadjuvant treatment do not impact survival.

12 June 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
ABAbu Bakar Hafeez Bhatti
Abu Bakar Hafeez Bhatti
WNWajih Naqvi
Wajih Naqvi
NKNusrat Yar Khan
Nusrat Yar Khan
HZHaseeb Haider Zia
Haseeb Haider Zia
FDFaisal Saud Dar
Faisal Saud Dar
ARAtif Rana
Atif Rana
Background: The indications for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) continue to evolve. The aim of this study was to report outcomes in patients who underwent living donor liver transplantation (LDLT) for HCC outside traditional criteria including macrovascular invasion (MVI). Methods: We reviewed outcomes in patients who met the University of California San Francisco (UCSF) criteria (n = 159) and our center-specific criteria (UCSF+) (largest tumor diameter ≤ 10 cm, any tumor number, AFP ≤ 1000 ng/ml) (n = 58). We also assessed outcomes in patients with MVI (n = 27). Results: The median follow was 28 (10.6–42.7) months. The 5 year overall survival and risk of recurrence (RR) in the UCSF and UCSF + group was 71% vs 69% (P = 0.7) and 13% vs 36% (P = 0.1) respectively. When patients with AFP > 600 ng/ml were excluded from the UCSF + group, RR was 27% (P = 0.3). Among patients with MVI who had downstaging (DS), 4/5(80%) in low-risk group (good response and AFP ≤ 100 ng/ml) and 2/10 (20%) in the high-risk group (poor response or AFP > 100 ng/ml) were alive at the last follow-up. When DS was not feasible, 3/3 (100%) in the low-risk group (AFP ≤ 100 ng/ml + Vp1-2 MVI) and 1/9 (9.1%) in the high-risk group (AFP > 100 or Vp3 MVI) were alive. The 5 year OS in the low-risk MVI group was 85% (P = 0.003). Conclusion: With inclusion of AFP, response to downstaging and degree of MVI, acceptable survival can be achieved with LDLT for HCC outside traditional criteria.

1 June 2018 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
ABAbu Bakar Hafeez Bhatti
Abu Bakar Hafeez Bhatti
FDFaisal S. Dar
Faisal S. Dar
MBMuhammad O. Butt
Muhammad O. Butt
ESEraj Sahaab
Eraj Sahaab
MSMohammad Salih
Mohammad Salih
NKNasir A. Khan
Nasir A. Khan